Last reviewed · How we verify
Chemotheraoy along
Chemotheraoy along works by inhibiting cell division in rapidly proliferating cancer cells.
Chemotheraoy along works by inhibiting cell division in rapidly proliferating cancer cells. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | Chemotheraoy along |
|---|---|
| Sponsor | Fujian Medical University |
| Drug class | Chemotherapeutic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Chemotheraoy along is a chemotherapeutic agent that interferes with DNA replication and transcription, ultimately leading to cell death. This mechanism is particularly effective against rapidly dividing cancer cells. The exact molecular target of Chemotheraoy along is not well-characterized.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotheraoy along CI brief — competitive landscape report
- Chemotheraoy along updates RSS · CI watch RSS
- Fujian Medical University portfolio CI